GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Approved drug Immunopharmacology Ligand
retifanlimab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interaction between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint modulator.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Retifanlimab was evaluated in trials as a monotherapy [2], and in combination with platinum-based chemotherapy, for a range of advanced cancers. It was granted FDA orphan drug designations for the treatment of anal cancer (March 2020) and Merkel cell carcinoma (October 2020). The EMA also granted orphan drug designation for anal cancer (October 2020). First FDA marketing approval was granted in March 2023 [3], for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma. In May 2025, the FDA approved retifanlimab with carboplatin and paclitaxel to treat inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal, and retifanlimab monotherapy for this type of cancer where disease has progressed on, or there is intolerance to, platinum-based chemotherapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04082364 Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3 Interventional MacroGenics MAHOGANY trial. 1
NCT04472429 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Phase 3 Interventional Incyte Corporation The POD1UM-303/InterAACT 2 study, was based on positive findings from the POD1UM-202 trial. 5
NCT03597295 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) Phase 2 Interventional Incyte Corporation The POD1UM-202 study was completed in November 2021. 4